Targeted Therapy Treatment Innovations in AML - Episode 8

5-Year Follow-Up Data For CPX-351 in AML

Alexandra S. Wolff, PharmD, BCOP, explores the 5-year follow-up data from the phase 3 trial of CPX-351 in AML.